RIBOLIFE-B (06938) Files Phase II Clinical Trial Application for RBD1119 Injection in Coronary Artery Disease Treatment

Stock News05-28 07:50

RIBOLIFE-B (06938) announced that it has successfully submitted a Phase II clinical trial application to the European Medicines Agency for its self-developed product, RBD1119 injection, intended for the treatment of Coronary Artery Disease (CAD). CAD is a leading global cause of morbidity and mortality, primarily driven by the formation of atherosclerotic plaques and associated thrombotic complications, such as myocardial infarction and other ischemic events. Despite the widespread use of standard therapies, including antiplatelet and anticoagulant treatments, patients with stable CAD continue to face a significant residual risk of thrombotic events even under optimized care. Current treatments are further limited by an increased risk of bleeding, which restricts their therapeutic intensity and long-term dosing regimens in many patients. RBD1119 injection represents a novel anti-thrombotic siRNA therapy designed to provide effective and durable protection against thrombosis while maintaining a favorable safety profile, particularly regarding bleeding risk.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1123219623?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-28 07:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1123219623","market":"sh","top_or_hot":-1,"title":"RIBOLIFE-B (06938) Files Phase II Clinical Trial Application for RBD1119 Injection in Coronary Artery Disease Treatment","media":"Stock News","content":"<p>RIBOLIFE-B (06938) announced that it has successfully submitted a Phase II clinical trial application to the European Medicines Agency for its self-developed product, RBD1119 injection, intended for the treatment of Coronary Artery Disease (CAD). CAD is a leading global cause of morbidity and mortality, primarily driven by the formation of atherosclerotic plaques and associated thrombotic complications, such as myocardial infarction and other ischemic events. Despite the widespread use of standard therapies, including antiplatelet and anticoagulant treatments, patients with stable CAD continue to face a significant residual risk of thrombotic events even under optimized care. Current treatments are further limited by an increased risk of bleeding, which restricts their therapeutic intensity and long-term dosing regimens in many patients. RBD1119 injection represents a novel anti-thrombotic siRNA therapy designed to provide effective and durable protection against thrombosis while maintaining a favorable safety profile, particularly regarding bleeding risk.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>RIBOLIFE-B (06938) Files Phase II Clinical Trial Application for RBD1119 Injection in Coronary Artery Disease Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRIBOLIFE-B (06938) Files Phase II Clinical Trial Application for RBD1119 Injection in Coronary Artery Disease Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-05-28 07:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>RIBOLIFE-B (06938) announced that it has successfully submitted a Phase II clinical trial application to the European Medicines Agency for its self-developed product, RBD1119 injection, intended for the treatment of Coronary Artery Disease (CAD). CAD is a leading global cause of morbidity and mortality, primarily driven by the formation of atherosclerotic plaques and associated thrombotic complications, such as myocardial infarction and other ischemic events. Despite the widespread use of standard therapies, including antiplatelet and anticoagulant treatments, patients with stable CAD continue to face a significant residual risk of thrombotic events even under optimized care. Current treatments are further limited by an increased risk of bleeding, which restricts their therapeutic intensity and long-term dosing regimens in many patients. RBD1119 injection represents a novel anti-thrombotic siRNA therapy designed to provide effective and durable protection against thrombosis while maintaining a favorable safety profile, particularly regarding bleeding risk.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"","article_id":"1123219623","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1123219623","pubTimestamp":1779925820,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"RIBOLIFE-B (06938) announced that it has successfully submitted a Phase II clinical trial application to the European Medicines Agency for its self-developed product, RBD1119 injection, intended for...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","06938":"瑞博生物-B"},"translate_title":"RIBOLIFE-B(06938)提交RBD1119注射液治疗冠状动脉疾病的II期临床试验申请","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06938":1},"content_text":"RIBOLIFE-B (06938) announced that it has successfully submitted a Phase II clinical trial application to the European Medicines Agency for its self-developed product, RBD1119 injection, intended for the treatment of Coronary Artery Disease (CAD). CAD is a leading global cause of morbidity and mortality, primarily driven by the formation of atherosclerotic plaques and associated thrombotic complications, such as myocardial infarction and other ischemic events. Despite the widespread use of standard therapies, including antiplatelet and anticoagulant treatments, patients with stable CAD continue to face a significant residual risk of thrombotic events even under optimized care. Current treatments are further limited by an increased risk of bleeding, which restricts their therapeutic intensity and long-term dosing regimens in many patients. RBD1119 injection represents a novel anti-thrombotic siRNA therapy designed to provide effective and durable protection against thrombosis while maintaining a favorable safety profile, particularly regarding bleeding risk.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.3","shortVersion":"4.42.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1123219623","isCrawlerRequest":true}